JP2022538301A5 - - Google Patents
Info
- Publication number
- JP2022538301A5 JP2022538301A5 JP2021577427A JP2021577427A JP2022538301A5 JP 2022538301 A5 JP2022538301 A5 JP 2022538301A5 JP 2021577427 A JP2021577427 A JP 2021577427A JP 2021577427 A JP2021577427 A JP 2021577427A JP 2022538301 A5 JP2022538301 A5 JP 2022538301A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- compound
- hydrogen
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025017657A JP2025065311A (ja) | 2019-06-27 | 2025-02-05 | Cns障害を治療するための組成物及び方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962867695P | 2019-06-27 | 2019-06-27 | |
| US201962867734P | 2019-06-27 | 2019-06-27 | |
| US201962867736P | 2019-06-27 | 2019-06-27 | |
| US62/867,736 | 2019-06-27 | ||
| US62/867,695 | 2019-06-27 | ||
| US62/867,734 | 2019-06-27 | ||
| PCT/US2020/040164 WO2020264512A1 (en) | 2019-06-27 | 2020-06-29 | Compounds for treating cns disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025017657A Division JP2025065311A (ja) | 2019-06-27 | 2025-02-05 | Cns障害を治療するための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022538301A JP2022538301A (ja) | 2022-09-01 |
| JP2022538301A5 true JP2022538301A5 (cg-RX-API-DMAC7.html) | 2023-07-11 |
| JP7670632B2 JP7670632B2 (ja) | 2025-04-30 |
Family
ID=71728948
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021577427A Active JP7670632B2 (ja) | 2019-06-27 | 2020-06-29 | Cns障害を治療するための組成物及び方法 |
| JP2025017657A Pending JP2025065311A (ja) | 2019-06-27 | 2025-02-05 | Cns障害を治療するための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025017657A Pending JP2025065311A (ja) | 2019-06-27 | 2025-02-05 | Cns障害を治療するための組成物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20230257415A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3990468A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7670632B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114729000A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020304679A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021026445A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3143545A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX428310B (cg-RX-API-DMAC7.html) |
| TW (1) | TWI896548B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020264512A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS62761B1 (sr) | 2012-08-21 | 2022-01-31 | Sage Therapeutics Inc | Alopregnanolon za lečenje refraktornog epileptičkog statusa |
| SMT202100509T1 (it) | 2013-04-17 | 2021-11-12 | Sage Therapeutics Inc | Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| WO2018013613A1 (en) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
| TW202604538A (zh) | 2016-08-23 | 2026-02-01 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| US20200291059A1 (en) | 2017-12-08 | 2020-09-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| AU2019357040B2 (en) | 2018-10-12 | 2025-03-27 | Sage Therapeutics, Inc. | Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of CNS disorders |
| IL312610B2 (en) | 2018-12-05 | 2026-05-01 | Sage Therapeutics Llc | Neuroactive steroids and methods of using them |
| CN111410678B (zh) | 2019-01-08 | 2023-02-28 | 成都康弘药业集团股份有限公司 | 甾体类化合物、用途及其制备方法 |
| JP7670626B2 (ja) | 2019-05-31 | 2025-04-30 | セージ セラピューティクス, インコーポレイテッド | 神経刺激性ステロイド及びその組成物 |
| JP7787635B2 (ja) | 2019-06-27 | 2025-12-17 | セージ セラピューティクス, エルエルシー | Cns障害を治療するための組成物及び方法 |
| AU2021238346A1 (en) | 2020-03-18 | 2022-09-29 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2969M (fr) * | 1963-05-22 | 1964-11-30 | Roussel Uclaf | Nouveau médicament notamment pour le traitement des spasmes d'origine coronarienne on viscérale. |
| ES432106A1 (es) * | 1973-11-30 | 1976-11-01 | Schering Ag | Procedimiento para la preparacion de d-homo-20-cetopregna- nos. |
| IL48628A0 (en) * | 1974-12-23 | 1976-02-29 | Schering Ag | D-homo-20-keto-pregnanes and process for their manufactur |
| GB1570394A (en) * | 1976-01-06 | 1980-07-02 | Glaxo Lab Ltd | 11-acyloxy-3-hydroxy steroids |
| GB1581234A (en) * | 1976-04-05 | 1980-12-10 | Glaxo Operations Ltd | 11a - amino - 3a - hydroxysteroids |
| GB1581235A (en) * | 1977-04-04 | 1980-12-10 | Glaxo Operations Ltd | 11a-amino-3a-hydroxy-steroids |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| BR9509764A (pt) * | 1994-11-23 | 1998-07-07 | Cocensys Inc | Série androstano e pregnano para modulação alostérica de receptor de gaba |
| AU3967297A (en) * | 1996-08-01 | 1998-02-25 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| SMT202100509T1 (it) | 2013-04-17 | 2021-11-12 | Sage Therapeutics Inc | Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia |
| DK3258939T3 (da) | 2015-02-20 | 2022-12-12 | Sage Therapeutics Inc | Neuroaktive steroider, sammensætninger og anvendelser heraf |
| WO2018013613A1 (en) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
| EP3728285B1 (en) | 2017-12-22 | 2026-04-08 | Sage Therapeutics, LLC | Compositions and methods for treating cns disorders |
| MX2020008182A (es) * | 2018-02-11 | 2020-09-22 | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Reguladores de derivados esteroides, metodo para prepararlos y usos de los mismos. |
| US12139508B2 (en) * | 2018-02-11 | 2024-11-12 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Steroid derivative regulators, method for preparing the same, and uses thereof |
| IL312610B2 (en) | 2018-12-05 | 2026-05-01 | Sage Therapeutics Llc | Neuroactive steroids and methods of using them |
-
2020
- 2020-06-29 CA CA3143545A patent/CA3143545A1/en active Pending
- 2020-06-29 WO PCT/US2020/040164 patent/WO2020264512A1/en not_active Ceased
- 2020-06-29 BR BR112021026445A patent/BR112021026445A2/pt unknown
- 2020-06-29 AU AU2020304679A patent/AU2020304679A1/en not_active Abandoned
- 2020-06-29 TW TW109121959A patent/TWI896548B/zh active
- 2020-06-29 JP JP2021577427A patent/JP7670632B2/ja active Active
- 2020-06-29 US US17/620,275 patent/US20230257415A1/en not_active Abandoned
- 2020-06-29 CN CN202080059462.4A patent/CN114729000A/zh active Pending
- 2020-06-29 EP EP20743477.0A patent/EP3990468A1/en active Pending
- 2020-06-29 MX MX2021015854A patent/MX428310B/es unknown
-
2023
- 2023-09-25 US US18/473,702 patent/US20240300996A1/en active Pending
-
2025
- 2025-02-05 JP JP2025017657A patent/JP2025065311A/ja active Pending